In re Effexor XR Antitrust Litigation
Oct, 2024
In re Effexor XR Antitrust Litigation (D.N.J.)
This antitrust lawsuit was filed against brand drug manufacturer Wyeth and generic drug manufacturer Teva, alleging that Wyeth and Teva violated federal antitrust laws by delaying the introduction of generic versions of Effexor XR into the United States market. Effexor XR is prescribed for the treatment of depression, anxiety, panic attacks, and social anxiety disorder.
The Court has preliminarily approved a settlement agreement for $39 million between Wyeth and a class of persons and entities that purchased brand or generic Effexor XR directly from Wyeth or Teva. Class members have rights that may be affected by the settlement.
The claims against Teva have not yet been settled; those claims are still being litigated.